suboxone 2 mg0.5 mg
naomi shaco-ezra ltd - buprenorphine hydrochloride; naloxone hydrochloride dihydrate - tablets sublingual - buprenorphine hydrochloride 2.16 mg; naloxone hydrochloride dihydrate 0.61 mg - buprenorphine - buprenorphine - substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. the intention of the naloxone component is to deter intravenous misuse.treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction.
suboxone 8 mg 2 mg
naomi shaco-ezra ltd - buprenorphine hydrochloride; naloxone hydrochloride dihydrate - tablets sublingual - buprenorphine hydrochloride 8.64 mg; naloxone hydrochloride dihydrate 2.44 mg - buprenorphine - buprenorphine - substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. the intention of the naloxone component is to deter intravenous misuse.treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction
fentanyl kalceks
kalceks jsc - fentanyl - solution for i/m and i/v injection - 0,05mg/ml
promedols
kalceks jsc - trimeperidine (trimeperidine hydrochloride) - solution for i/m, i/v and s/c injection - 20mg/ml
morfina hydrohlorids-kalceks
kalceks jsc - morphine hydrochloride - solution for i/v, i/m and s/c injection - 10mg/ml
adjupanrix (previously pandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals)
glaxosmithkline biologicals s.a. - split influenza virus, inactivated, containing antigen: a/vietnam/1194/2004 (h5n1) like strain used (nibrg-14) - influenza, human, immunization, disease outbreaks - vaccines, - prophylaxis of influenza in an officially declared pandemic situation. pandemic influenza vaccine should be used in accordance with official guidance.,
morfina hidrohlorids-kalceks solution for injection
kalceks jsc - morphine (morphine hydrochloride) - solution for injection - 10mg/ml
ecokinase
roche registration ltd. - reteplase - myocardial infarction - antithrombotic agents - thrombolytic therapy of acute myocardial infarction
bovilis btv8
intervet international bv - bluetongue virus vaccine, serotype 8 (inactivated) - inactivated viral vaccines, bluetongue virus, sheep - sheep; cattle - cattle to stimulate active immunity in sheep from 6 weeks of age against bluetongue virus serotype 8 to reduce viraemia sheep to stimulate active immunity in sheep from 1 month of age against bluetongue virus serotype 8 to prevent viraemia,
zulvac 1 bovis
zoetis belgium sa - inactivated bluetongue virus, serotype 1 - immunologicals - cattle - active immunisation of cattle from 2½ months of age for the prevention of viraemia caused by bluetongue virus, serotype 1.onset of immunity: 15 days after completion of the primary vaccination course.duration of immunity: 12 months.